ICAD, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 USD | -0.68% |
|
-4.55% | -16.95% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the iCAD, Inc. Second Qu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Companyâs Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.47
USD
Average target price
4.833
USD
Spread / Average Target
+228.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.95% | 38.74M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- ICAD Stock
- News iCAD, Inc.
- Transcript : ICAD, Inc., Q2 2023 Earnings Call, Aug 14, 2023
